Leifheit Aktiengesellschaft

  • WKN: 646450
  • ISIN: DE0006464506
  • Land: Deutschland

Analyst Coverage

Datum Empfehlung Target Price Institute PDF
2/10/2018 Leifheit hold 31.00 EUR Landesbank Baden-Württemberg Download
2/9/2018 Leifheit hold 28.00 EUR Bankhaus Lampe Research
11/30/2017 Leifheit hold 28.00 EUR Bankhaus Lampe Research Download
11/30/2017 Leifheit buy 35.00 EUR GSC Research GmbH
11/10/2017 Leifheit hold 31.50 EUR Bankhaus Lampe Research Download
11/9/2017 Leifheit hold 30.00 EUR Berenberg Bank Download
11/9/2017 Leifheit hold 31.00 EUR Landesbank Baden-Württemberg Download
9/21/2017 Leifheit hold 31.00 EUR Landesbank Baden-Württemberg Download
9/19/2017 Leifheit hold 31.50 EUR Bankhaus Lampe Research Download
9/19/2017 Leifheit hold 33.00 EUR Berenberg Bank Download
9/18/2017 Leifheit hold 32.50 EUR Bankhaus Lampe Research Download
8/11/2017 Leifheit hold 32.50 EUR Bankhaus Lampe Research Download
8/10/2017 Leifheit hold 36.00 EUR Landesbank Baden-Württemberg Download
8/10/2017 Leifheit hold 34.50 EUR Berenberg Bank Download
8/4/2017 Leifheit hold 32.50 EUR Bankhaus Lampe Research Download
6/29/2017 Leifheit hold 36.00 EUR Landesbank Baden-Württemberg Download
5/12/2017 Leifheit hold 69.00 EUR Berenberg Bank Download
5/15/2017 Leifheit hold 71.00 EUR Landesbank Baden-Württemberg Download
5/5/2017 Leifheit hold 65.00 EUR Bankhaus Lampe Research Download

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021